Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.77 |
| ▸ | HTT | P42858 | 2/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.77 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.77 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.77 |
| ▸ | RAB9A | P51151 | 1/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.77 |
| ▸ | TOP2A | P11388 | 2/20 | 0.53 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13522800 | 0.92 | HTT (0.70) | ALDH1A1HTTKDM4EPTBP1OPRK1 | |
| SCHEMBL9319986 | 0.87 | ALDH1A1 (1.00) | ALDH1A1HTTKDM4EPTBP1OPRK1 | |
| SCHEMBL21994255 | 0.87 | ALDH1A1 (1.00) | ALDH1A1HTTKDM4EPTBP1OPRK1 | |
| SCHEMBL16675032 | 0.84 | ALDH1A1 (0.69) | ALDH1A1HTTKDM4EPTBP1OPRK1 | |
| SCHEMBL31690659 | 0.82 | TOP2A (0.59) | ALDH1A1HTTKDM4EPTBP1OPRK1 | |
| SCHEMBL1025639 | 0.82 | TOP2A (0.77) | ALDH1A1HTTKDM4EPTBP1OPRK1 | |
| SCHEMBL16675037 | 0.79 | KDM4E (0.57) | ALDH1A1HTTKDM4EPTBP1OPRK1 | |
| SCHEMBL1025295 | 0.77 | SMN1; SMN2 (0.59) | ALDH1A1KDM4ERAB9ASMN1; SMN2TOP2A | |
| SCHEMBL1024423 | 0.77 | TOP2A (0.75) | ALDH1A1HTTKDM4EPTBP1OPRK1 | |
| SCHEMBL22056109 | 0.75 | KDM4E (0.72) | ALDH1A1HTTKDM4EPTBP1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10012659-B2 | Methods for diagnosing iron-related pathologies | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2018-07-03 | — | — | US | claimed |
| EP-2945629-A1 | CHEMOTHERAPY FOR DRUG-RESISTANT CANCER CELLS | ONCOCHEL THERAPEUTICS LLC (US) | 2015-11-25 | — | — | EP | claimed |
| US-20150306081-A1 | Chemotherapy for Drug-Resistant Cancer Cells | Oncochel Therapeutics LLC (US) | 2015-10-29 | — | — | US | claimed |
| WO-2014078898-A1 | CHEMOTHERAPY FOR DRUG-RESISTANT CANCER CELLS | THE UNIVERSITY OF SYDNEY (AU) | 2014-05-30 | — | — | WO | claimed |
| EP-1608623-B1 | METAL ION CHELATORS AND THERAPEUTIC USE THEREOF | RICHARDSON DESI RAYMOND (AU) | 2011-01-19 | — | — | EP | claimed |
| US-10012659-B2 | Methods for diagnosing iron-related pathologies | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170016923-A1 | METHODS FOR DIAGNOSING IRON-RELATED PATHOLOGIES | THE ARIZONA BOARD OF REGENTS OF BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2017-01-19 | — | — | US | disclosed |
| EP-2945629-A1 | CHEMOTHERAPY FOR DRUG-RESISTANT CANCER CELLS | ONCOCHEL THERAPEUTICS LLC (US) | 2015-11-25 | — | — | EP | disclosed |
| US-20150306081-A1 | Chemotherapy for Drug-Resistant Cancer Cells | Oncochel Therapeutics LLC (US) | 2015-10-29 | — | — | US | disclosed |
| US-20150306081-A1 | Chemotherapy for Drug-Resistant Cancer Cells | Oncochel Therapeutics LLC (US) | 2015-10-29 | — | — | US | disclosed |
| WO-2015142882-A1 | METHODS FOR DIAGNOSING IRON-RELATED PATHOLOGIES | THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2015-09-24 | — | — | WO | disclosed |
| WO-2014078898-A1 | CHEMOTHERAPY FOR DRUG-RESISTANT CANCER CELLS | THE UNIVERSITY OF SYDNEY (AU) | 2014-05-30 | — | — | WO | disclosed |
| EP-1608623-B1 | METAL ION CHELATORS AND THERAPEUTIC USE THEREOF | RICHARDSON DESI RAYMOND (AU) | 2011-01-19 | — | — | EP | disclosed |
| EP-1608623-B1 | METAL ION CHELATORS AND THERAPEUTIC USE THEREOF | RICHARDSON DESI RAYMOND (AU) | 2011-01-19 | — | — | EP | disclosed |
| WO-2010000008-A1 | THIOSEMICARBAZONE COMPOUNDS AND USE THEREOF | RICHARDSON DESI RAYMOND (AU) | 2010-01-07 | — | — | WO | disclosed |
| EP-1608623-A4 | METAL ION CHELATORS AND THERAPEUTIC USE THEREOF | NEWSOUTH INNOVATIONS PTY LTD (AU) | 2007-07-18 | — | — | EP | disclosed |
| US-20060252798-A1 | Metal ion chelators and therapeutic use thereof | RICHARDSON, DESI (AU) | 2006-11-09 | — | — | US | disclosed |
| EP-1608623-A1 | METAL ION CHELATORS AND THERAPEUTIC USE THEREOF | UNISEARCH LIMITED (AU) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004069801-A1 | METAL ION CHELATORS AND THERAPEUTIC USE THEREOF | UNISEARCH LIMITED (AU) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150306081-A1 | Chemotherapy for Drug-Resistant Cancer Cells | ABCC1, SLC47A1, ABCB1 | ALDH1A1 285/4885HTT 1969/4885KDM4E 3114/4885 |
| US-20060252798-A1 | Metal ion chelators and therapeutic use thereof | SLC40A1, SLC30A6, SLC39A3 | ALDH1A1 1212/4885HTT 448/4885KDM4E 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.